Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.
Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment. In this study, we established that cells acqu...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4431826?pdf=render |
id |
doaj-5dd0668e98ba4731bda57b85b45b89bb |
---|---|
record_format |
Article |
spelling |
doaj-5dd0668e98ba4731bda57b85b45b89bb2020-11-25T01:24:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012683010.1371/journal.pone.0126830Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.Seung Ho ChoiHye Kyung HongYong Beom ChoWoo Yong LeeHae Yong YooIrinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment. In this study, we established that cells acquire chronic resistance to irinotecan. We profiled their differential gene expression using microarray. After gene ontology (GO) and KEGG pathway analysis of the microarray data, we specifically investigated whether Sestrin3 could decrease irinotecan resistance. Our results revealed that Sestrin3 enhanced the anticancer effect of irinotecan in vitro in LoVo cells that had acquired resistance to irinotecan. Irinotecan-resistant LoVo cells showed lower reactive oxygen species (ROS) production than their irinotecan-sensitive parental cells. ROS production was increased by Sestrin3 knockdown in irinotecan-resistant LoVo cells. Our results indicate that Sestrin3 might be a good target to develop therapeutics that can help to overcome resistance to irinotecan.http://europepmc.org/articles/PMC4431826?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seung Ho Choi Hye Kyung Hong Yong Beom Cho Woo Yong Lee Hae Yong Yoo |
spellingShingle |
Seung Ho Choi Hye Kyung Hong Yong Beom Cho Woo Yong Lee Hae Yong Yoo Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. PLoS ONE |
author_facet |
Seung Ho Choi Hye Kyung Hong Yong Beom Cho Woo Yong Lee Hae Yong Yoo |
author_sort |
Seung Ho Choi |
title |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. |
title_short |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. |
title_full |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. |
title_fullStr |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. |
title_full_unstemmed |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan. |
title_sort |
identification of sestrin3 involved in the in vitro resistance of colorectal cancer cells to irinotecan. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment. In this study, we established that cells acquire chronic resistance to irinotecan. We profiled their differential gene expression using microarray. After gene ontology (GO) and KEGG pathway analysis of the microarray data, we specifically investigated whether Sestrin3 could decrease irinotecan resistance. Our results revealed that Sestrin3 enhanced the anticancer effect of irinotecan in vitro in LoVo cells that had acquired resistance to irinotecan. Irinotecan-resistant LoVo cells showed lower reactive oxygen species (ROS) production than their irinotecan-sensitive parental cells. ROS production was increased by Sestrin3 knockdown in irinotecan-resistant LoVo cells. Our results indicate that Sestrin3 might be a good target to develop therapeutics that can help to overcome resistance to irinotecan. |
url |
http://europepmc.org/articles/PMC4431826?pdf=render |
work_keys_str_mv |
AT seunghochoi identificationofsestrin3involvedintheinvitroresistanceofcolorectalcancercellstoirinotecan AT hyekyunghong identificationofsestrin3involvedintheinvitroresistanceofcolorectalcancercellstoirinotecan AT yongbeomcho identificationofsestrin3involvedintheinvitroresistanceofcolorectalcancercellstoirinotecan AT wooyonglee identificationofsestrin3involvedintheinvitroresistanceofcolorectalcancercellstoirinotecan AT haeyongyoo identificationofsestrin3involvedintheinvitroresistanceofcolorectalcancercellstoirinotecan |
_version_ |
1725119053366820864 |